Brief: Dogwood Therapeutics Announces Commencement Of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2B Long Term Extension Study
18/05/2026 14:27
May 18 (Reuters) - Dogwood Therapeutics Inc DWTX.O: DOGWOOD THERAPEUTICS ANNOUNCES COMMENCEMENT OF HALNEURON® CHEMOTHERAPY INDUCED NEUROPATHIC PAIN PHASE 2B LONG TERM EXTENSION STUDY DOGWOOD THERAPEUTICS INC - EXTENSION TRIAL DATA TO SUPPORT FDA SUBMISSION FOR PHASE 3 PROGRAM IN H1 2027 DOGWOOD THERAPEUTICS INC - TOP-LINE RESULTS FROM DOUBLE-BLINDED CINP STUDY EXPECTED IN FALL 2026 Source text: ID:nGNX7v8kq Further company coverage: DWTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Dogwood Therapeutics
See all newsDogwood Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Dogwood Therapeutics Q2 net loss widens on higher costs, impairment charge
Brief: Dogwood Therapeutics Q2 EPS USD -0.34
Dogwood Therapeutics Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: Dogwood Therapeutics Announces Commencement Of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2B Long Term Extension Study